Drug intelligence / Profile preview

优威克

Development stage
Unknown
Lead developer
Zhifei Biological
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

**优威克** is Zhifei's marketed 23-valent pneumococcal polysaccharide vaccine for prevention of infections caused by vaccine-included *Streptococcus pneumoniae* serotypes in people aged 2 years and older. Developed and manufactured by Beijing Zhifei Lvzhu Biopharmaceutical, it contains purified capsular polysaccharide antigens from 23 pneumococcal serotypes and induces serotype-specific humoral antibody responses. It is a non-conjugated polysaccharide vaccine and is not expected to protect against pneumococcal serotypes not represented in the formulation. Zhifei lists 优威克 as its proprietary 23-valent pneumococcal polysaccharide vaccine product, and the product received Chinese marketing authorization in 2023. ([zhifeishengwu.com](https://www.zhifeishengwu.com/zh_CN/pro/27.html))

Brand names
优威克
Other names
23价肺炎球菌多糖疫苗23-valent pneumococcal polysaccharide vaccineYouweike
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on 优威克.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 优威克.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call